ArticleCureus2024
Role of 2-Deoxy-D-Glucose in Enhancing the Efficacy of Standard of Care for Moderate to Severe COVID-19: A Comparative Analysis of Clinical Outcomes.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metabolic control of macrophages in coronavirus disease 2019.Virulence · 2026Review
- Metabolic Reprogramming in Respiratory Viral Infections: A Focus on SARS-CoV-2, Influenza, and Respiratory Syncytial Virus.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective This study aimed to evaluate the role of 2-Deoxy-D-Glucose (2-DG) in moderate to severe Coronavirus Disease 2019 (COVID-19) cases. Methodology This study retrospectively analyzed the effects of 2-DG alongside Standard of Care (SOC) for moderate to severe COVID-19 in 150 patients. Eligible patients were aged 18-65, with confirmed COVID-19, who met clinical criteria for moderate or severe illness. Data collected included demographics, clinical status, treatment details, and outcomes, evaluated using the WHO's 10-point scale. The primary outcome measured was time to clinical improvement, with secondary outcomes including duration of oxygen supplementation, length of hospital stay, and viral clearance. Data analysis employed the Cox proportional hazard model, with significance at p < 0.05. Results In the study, initial oxygen saturation levels upon admission were similar between groups, averaging 92.6% in the 2-DG with SOC group and 91.8% in the SOC-only group (p = 0.97). The WHO ordinal scores, pulse, and respiratory rates improved significantly in the 2-DG group across multiple intervals. Oxygen supplementation needs to be decreased notably, with 2-DG patients requiring an average of 5.1 L/min by Day 5, showing significant reductions compared to the SOC group. The time to clinical improvement and length of hospital stay were also shorter in the 2-DG group (5.2 days vs. 7.5 days; 8.5 days vs. 10.5 days, respectively; p < 0.001). Adverse events were less frequent in the 2-DG group (6.7% vs. 13.3%, p = 0.03). Conclusion In conclusion, 2-DG demonstrates significant efficacy as an adjunct therapy for moderate to severe COVID-19, reducing both time to clinical improvement (5.2 vs. 7.5 days, p < 0.001) and hospital stay duration. Additionally, fewer adverse events were reported, and viral clearance rates were higher in the 2-DG group. These findings highlight 2-DG's potential to improve clinical outcomes in COVID-19 care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.